期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 24, 期 1, 页码 105-120出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14656566.2022.2108702
关键词
Antiandrogens; GLP-1; GLP-1 receptor agonists; incretin mimetics; inositol; kisspeptin-neurokinin B antagonists; oral contraceptives; PCOS; SGLT2 inhibitors
This article provides an overview of pharmacotherapies for the management of women with polycystic ovary syndrome (PCOS) who do not seek pregnancy. It emphasizes the need for individualized treatment and targeting specific symptoms. However, the complexity and heterogeneity of PCOS pose challenges in finding safer and more effective therapeutic strategies.
Introduction Polycystic ovary syndrome (PCOS) is a common hormonal, metabolic, and reproductive disorder with a heterogeneous phenotype. As the exact etiology of PCOS is still unclear, available pharmacotherapies are mostly directed toward alleviating symptoms and associated metabolic abnormalities. Areas covered Herein, we present an overview of the current and emerging pharmacotherapies for the management of women with PCOS who do not seek pregnancy. We performed a literature search in PubMed database up to January 2022 and reviewed papers assessing drug treatments for PCOS. We aimed to outline the most recent evidence to support treatment recommendations in these patients. Expert opinion Targets for medical treatment include hormonal, reproductive, and metabolic abnormalities in PCOS. However, none of the available pharmacological options can cover the entire spectrum of clinical manifestations observed in these patients. Considering the heterogeneity of PCOS, treatment should be individualized and adapted to specific needs of each patient. Better understanding of the molecular mechanisms underlying the pathogenesis of PCOS would help development of novel, safer, and more effective multi-targeted therapeutic strategies for the syndrome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据